Literature DB >> 15351398

Design, synthesis, and biological evaluation of cytotoxic 11-aminoalkenylindenoisoquinoline and 11-diaminoalkenylindenoisoquinoline topoisomerase I inhibitors.

Xiangshu Xiao1, Smitha Antony, Glenda Kohlhagen, Yves Pommier, Mark Cushman.   

Abstract

The cytotoxic indenoisoquinolines are a novel class of noncamptothecin topoisomerase I inhibitors having certain features that compare favorably with the camptothecins. A new strategy was adopted to attach aminoalkenyl substituents at C-11 of the indenoisoquinoline ring system, which, according to molecular modeling, would orient the side chains toward the DNA minor groove. All of the newly synthesized compounds were more cytotoxic than the parent indenoisoquinoline NSC 314622. Despite an imperfect correlation between cytotoxicities and topoisomerase I inhibition results, the hypothetical structural model of the cleavage complex presented here provides a conceptual framework to explain the structure-activity relationships.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15351398     DOI: 10.1016/j.bmc.2004.07.027

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  16 in total

1.  A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.

Authors:  Christophe Marchand; Smitha Antony; Kurt W Kohn; Mark Cushman; Alexandra Ioanoviciu; Bart L Staker; Alex B Burgin; Lance Stewart; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2006-02       Impact factor: 6.261

2.  A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor.

Authors:  Andrew Morrell; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

3.  Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures.

Authors:  Andrew Morrell; Michael S Placzek; Jamin D Steffen; Smitha Antony; Keli Agama; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2007-04-03       Impact factor: 7.446

4.  Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles.

Authors:  Muthukaman Nagarajan; Andrew Morrell; Alexandra Ioanoviciu; Smitha Antony; Glenda Kohlhagen; Keli Agama; Melinda Hollingshead; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

5.  A Facile method to transform trans-4-carboxy-3,4-dihydro-3-phenyl- 1(2H)-isoquinolones to indeno[1,2-c]isoquinolines.

Authors:  Xiangshu Xiao; Mark Cushman
Journal:  J Org Chem       Date:  2005-08-05       Impact factor: 4.354

6.  Identification of a new endogenous metabolite and the characterization of its protein interactions through an immobilization approach.

Authors:  Jarosław Kalisiak; Sunia A Trauger; Ewa Kalisiak; Hirotoshi Morita; Valery V Fokin; Mike W W Adams; K Barry Sharpless; Gary Siuzdak
Journal:  J Am Chem Soc       Date:  2009-01-14       Impact factor: 15.419

7.  Microscopic Modes and Free Energies for Topoisomerase I-DNA Covalent Complex Binding with Non-campothecin Inhibitors by Molecular Docking and Dynamics Simulations.

Authors:  Ning-Ning Wei; Adel Hamza; Ce Hao; Zhilong Xiu; Chang-Guo Zhan
Journal:  Theor Chem Acc       Date:  2013-08       Impact factor: 1.702

8.  The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.

Authors:  Yves Pommier; Mark Cushman
Journal:  Mol Cancer Ther       Date:  2009-04-21       Impact factor: 6.261

Review 9.  DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition.

Authors:  Yves Pommier
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

10.  Orally bioavailable potent soluble epoxide hydrolase inhibitors.

Authors:  Sung Hee Hwang; Hsing-Ju Tsai; Jun-Yan Liu; Christophe Morisseau; Bruce D Hammock
Journal:  J Med Chem       Date:  2007-07-06       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.